No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MRK240726C122000
- 3.50
- +0.80+29.63%
15min DelayClose Jul 24 16:00 ET
3.50High3.25Low
3.30Open2.70Pre Close113 Volume209 Open Interest122.00Strike Price38.39KTurnover31.44%IV-0.33%PremiumJul 26, 2024Expiry Date3.92Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9099Delta0.0537Gamma30.82Leverage Ratio-0.1152Theta0.0065Rho28.05Eff Leverage0.0156Vega
Intraday
- 5D
- Daily
News
Preventive monoclonal antibody from Merck (MRK.US) achieves positive results, used for preventing infant RSV infection.
Merck (MRK.US) announced that the investigational respiratory syncytial virus (RSV) prophylactic monoclonal antibody clesrovimab (MK-1654) has obtained positive results in phase 2b/3 clinical trials.
Acquiring the company for over 1.3 billion US dollars! Merck's (MRK.US) new small-molecule cancer drug has entered phase 3 clinical trials in China.
According to the latest announcement by China's drug clinical trial registration and information disclosure platform, Merck (MRK.US) has initiated a Phase III clinical study for a new oral drug, MK-3543 (bomedemstat), for the treatment of primary thrombocytosis.
Merck & Co To Go Ex-Dividend On September 16th, 2024 With 0.77 USD Dividend Per Share
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
Merck Declares $0.77 Dividend
Express News | Merck & Co Inc - Has Declared a Quarterly Dividend of $0.77 per Share of Company's Common Stock for Q4 of 2024.
Comments
$Merck & Co(MRK.US$ Gild's new drug gonna take 500M revenue off MRK.
On Saturday, Donald Trump was shot at a campaign rally in Pennsylvania, which could be a key moment that completely disrupts the US election landscape this year. Following the incident, data from Polymarket shows that Trump's chances of winning the election have skyrocketed to 71%.
After shooting, Bitcoin price briefly surpassed $63,000. $Trump Media & Technology(DJT.US$ surged over 70% in Mond...
After shooting, Bitcoin price briefly surpassed $63,000. $Trump Media & Technology(DJT.US$ surged over 70% in Mond...
129
25
President Joe Biden, 81, has stated he remains committed to his re-election campaign despite slipping polling numbers and concerns about his recent public performances.
Reports suggest Biden acknowledged the importance of his upcoming appearances, though the White House denies this claim. His stumbling debate performance and questions about his mental acuity have caused panic within the Democratic Party, leading to speculation about a...
Reports suggest Biden acknowledged the importance of his upcoming appearances, though the White House denies this claim. His stumbling debate performance and questions about his mental acuity have caused panic within the Democratic Party, leading to speculation about a...
90
18
$Merck & Co(MRK.US$I think it’s just a temp pullback, it just broke the double-bottom line as well as the recent resistence simetanously. The pullback volume is also lower. Expecting new ATH.
5
$Merck & Co(MRK.US$ on the prowl for acquisitions up to $15 billion.
$Merck & Co(MRK.US$ already has an active partnership with $Janux Therapeutics(JANX.US$ for two TRACtr targets, and CEO Davis has evinced a preference for acquisition of $SPDR S&P Biotech ETF(XBI.US$ in which $Merck & Co(MRK.US$ already has a seat at the table.
$Merck & Co(MRK.US$ acquisition of $HARP earlier this year (for a song) shows their interest in the T Cell engag...
$Merck & Co(MRK.US$ already has an active partnership with $Janux Therapeutics(JANX.US$ for two TRACtr targets, and CEO Davis has evinced a preference for acquisition of $SPDR S&P Biotech ETF(XBI.US$ in which $Merck & Co(MRK.US$ already has a seat at the table.
$Merck & Co(MRK.US$ acquisition of $HARP earlier this year (for a song) shows their interest in the T Cell engag...
+1
9
Read more